Hi all, thanks for doing this. Liquid biopsies seem to be very effective at determining probability of recurrence when samples can be referenced to observed tumor mutations. How does this work with no patient matched tumor genome?

Also, the prevalence of ovarian cancer is relatively low among the general population, which I imagine makes the test more difficult. A test of high sensitivity (>95%) would still lead to many false positives. Is this a concern?